Aquestive Therapeutics Inc
NASDAQ:AQST

  • LAST PRICE
    2.5900
  • TODAY'S CHANGE (%)
    0.1700 (7.0248%)
  • Bid / Lots
    2.5600/ 6
  • Ask / Lots
    2.6000/ 10
  • Open / Previous Close
    2.4200 / 2.4200
  • Day Range
    2.4200
    2.6000
  • 52 Week Range
    1.2514
    6.2300
  • Volume
    1,701,035

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AQST
Aquestive Therapeutics Inc
220.3M
-6.1x
---
SMTI
Sanara Medtech Inc
241.6M
-49.5x
---
RDY
Dr Reddy's Laboratories Ltd
12.1B
18.9x
+24.18%
OPTN
OptiNose Inc
149.2M
-4.0x
---
INBP
Integrated Biopharma Inc
6.0M
-49.3x
---
QLI
Qilian International Holding Group Ltd
21.8M
-2.8x
---
As of 2024-06-27

Company Information

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Contact Information

Headquarters
30 Technology DrWARREN, NJ, United States 07059-5166
Phone
908-941-1900
Fax
302-636-5454

Executives

Independent Chairman of the Board
Gregory Brown
President, Chief Executive Officer, Director
Daniel Barber
Independent Vice Chairman of the Board
John Cochran
Chief Financial Officer
A. Ernest Toth
Chief Operating Officer
Cassie Jung

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$220.3M
Revenue (TTM)
$51.5M
Shares Outstanding
91.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.78
EPS
$-0.43
Book Value
$-1.55
P/E Ratio
-6.1x
Price/Sales (TTM)
4.3
Price/Cash Flow (TTM)
---
Operating Margin
-39.77%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.